[en] Background: Hepatitis C virus genotype 4 (HCV-4) is the most prevalent genotype in Central Africa. A large population of Black African individuals, among whom HCV-4 infection is widespread, resides in Belgium.
Aim: To compare epidemiology, clinical characteristics and any differences in receipt of HCV therapy in two populations of HCV-4 patients residing in Belgium.
Methods: This retrospective multicenter study selected 473 patients from seven hospital databases and compared them according to ethnic origin, i.e., Black African (n=331) or not (n=142), for epidemiological, clinical, biological and histological characteristics. Interleukin 28B polymorphism (CC-genotype) was evaluated in a second cohort of 69 Black African and 30 non-Black African patients.
Results: Compared to other patients, the Black African patients were more likely to be female and were older, more commonly overweight, more frequently had abnormal glucose metabolism and arterial hypertension; they were less likely to have dyslipidemia, a history of alcohol consumption or ALT elevation. The route of infection was more frequently unknown in Black African than in other patients. Black African patients had more HCV-4 subtypes, were less frequently of IL28B CC-genotype and had less severe liver fibrosis. The proportion of patients who received antiviral treatment was similar in the two groups.
Conclusion: In this Belgian cohort, patients with HCV-4 infection were more frequently of Black African origin than of other origin. Infected Black African patients were more commonly female, older at diagnosis, and had more co-morbidities than other patients; they also had less advanced liver fibrosis than infected non-Black African patients and fewer had a CC genotype. The number of patients treated with antiviral therapy was similar in the two groups.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Nkuize, M
Mulkay, JP
Moreno, C
Lasser, L
Michielsen, P
de Galocsy, C
Scheen, R
Assene, C
DELWAIDE, Jean ; Centre Hospitalier Universitaire de Liège - CHU > Gastro-Entérologie-Hépatologie
Language :
English
Title :
Ethnic epidemiological profiles and antiviral therapy among patients infected with hepatitis C virus genotype 4: a multicenter study from Belgium.
Madhava V., Burgess C., Drucker E. Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa. Lancet Infect. Dis., 2002, 2: 293-302.
Simmonds P. Genetic diversity and evolution of hepatitis C virus-15 years on. J. Gen. Virol., 2004, 85: 3173-3188.
Kamal S.M., Nasser I.A. Hepatitis C genotype 4: what we know and what we don't yet know Hepatology, 2008, 47: 1371-1383.
Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well ? Ann. Intern. Med., 2004, 140: 370-381.
Hnatyzyn H.J. Chronic hepatitis C and genotyping: the clinical significance of determining HCV genotypes. Antiviral. Ther., 2005, 10: 1-11.
Pybus O., Charleston M., Gupta S., Rambaut A., Holmes E., Harvey P. The epidemic behaviour of the hepatitis C virus. Science, 2001, 292: 2323-2325.
Mc Omish F., Yap P.L., Dow B.C., Follett E.A., Seed C., Keller A.J. et al. Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey. J. Clin. Microbiol., 1994, 32: 884-892.
Roulot D., Bourcier V., Grando V., Deny P., Baazia Y., Fontaine H. et al. Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. J. Viral. Hep., 2007, 14: 460-467.
Karoney M.J., Siika A.M. Hepatitis C virus (HCV) infection in Africa: a review. Pan Afr. Med. J., 2013, 6: 44.
Martinot-Peignoux M., Roudot-Thoroval F., Mendel I., Coste J., Izopet J., Duverlie G. et al. Hepatitis C virus genotypes in France: relationship with epidemiology, pathogenicity and response to interferon therapy. J. Viral. Hep., 1999, 6: 435-443.
Delwaide J., Reenaers C., Gerard C., Vaira D., Bastens B., Servais B. et al. HCV genotype 4 in Belgium: three distinct patterns among patients from European and African origin. Eur. J. Gastroenterol. Hepatol., 2006, 18: 707-712.
Ray S.C., Arthur R.R., Carella A., Bukh J., Thomas D.L. Genetic epidemiology of hepatitis C virus throughout Egypt. J. Infect. Dis., 2000, 182: 698-707.
Abdulkarim A.S., Zein N.N., Germer J.J., Kolbert C.P., Kabbani L., Krajnik K.L. et al. Hepatitis C virus genotypes and hepatitis G virus in hemodialysis patients from Syria: identification of two novel hepatitis C virus subtypes. Am. J. Trop. Med. Hyg., 1998, 59: 571-576.
Ndjomou J., Kupfer B., Kochan B., Zekeng L., Kaptue L., Matz B. Hepatitis C virus infection and genotypes among human immunodeficiency virus high-risk groups in Cameroon. J. Med. Virol., 2002, 66: 179-186.
Delaporte E., Thiers V., Dazza M.C. et al. High level of hepatitis C endemicity in Gabon, equatorial Africa. Trans. R. Soc. Trop. Med. Hyg., 1993, 87: 636-637.
Sanchez-Quijano A., Antonia A.M., Torronteras R., Romeo R., Mlika-Cabanne N., Aptel I. et al. Unexpected high prevalence of hepatitis C virus genotype 4 in Southern Spain. J. Hepatol., 1997 27: 25-29.
Cenci M., Massi M., Alderisio M., De Soccio G., Recchia O. Prevalence of hepatitis C virus (HCV) genotypes and increase of type 4 in central Italy: an update and report of new method of HCV genotyping. Anticancer Res., 2007, 27: 1219-1222.
Nicot F., Legrand-Abravanel F., Sandres-Saune K., Boulestin A., Dubois M., Alric L. et al. Heterogeneity of hepatitis C virus genotype 4 strains circulating in south-western France. J. Gen. Virol., 2005, 86: 107-114.
Gerard C., Delwaide J., Vaira D., Bastens B., Servais B., Wain E. et al. Evolution over a ten years period of the epidemiological profile of 1726 newly diagnosed HCV patients in Belgium. J. Med. Virol., 2005, 76: 503-510.
Poynard T., Bedossa P., Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet, 1997, 22: 825-832.
Poynard T., Ratziu V., Charlotte F., Goodman Z., McHutchison J., Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J. Hepatol., 2001, 34: 730-739.
Centre pour l'égalité des chances et la lutte contre le racisme. Migrations et populations issues de l'immigration en Belgique: rapport statistique et démographique http://www.diversite.be/sites/default/files/documents/publication/ rapport_statistique_et_ demographique.pdf
Centre pour l'égalité des chances et la lutte contre le racisme, Rapport statistique et démographique, 2013: Migrations et populations issues de l'immigration en Belgique, Bruxelles, 175p.
Poynard T., Bedossa P., Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet, 1997, 22: 825-832.
Poynard T., Ratziu V., Charlotte F., Goodman Z., Mc Hutchison J., Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J. Hepatol., 2001, 34: 730-739.
Sersté T., Nkuize M., Moucari R., Van Gossum M., Reynders M., Scheen R. et al. Metabolic disorders associated with chronic hepatitis C: impact of genotype and ethnicity. Liver Intern, 2010, 30: 1131-1136.
Moucari R., Asselah T., Cazals-Hatem D., Voitot H., Boyer N., Ripault M.P. et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterol., 2008, 134: 416-423.
Conjeevaram H.S., Kleiner D.E., Everhart J.E., Hoofnagle J.H., Zacks S., Afdhal N.H. et al. Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology, 2007, 45: 80-87.
Schwimmer J.B., McGreal N., Deutsch R., Finegold M.J., Lavine J.E. Influence of gender, race, and ethnicity on suspected fatty liver in obese adolescents. Pediatrics, 2005, 115: 561-565.
Candotti D., Mundy C., Kadewele G., Nkhoma W., Bates I., Allain J. Serological and molecular screening for viruses in blood donors from Ntcheu, Malawi: high prevalence of HIV-1 subtype C and of markers of hepatitis B and C viruses. J. Med. Virol., 2001, 65: 1-5.
Wiley T.E., Brown J., Chan J. Hepatitis C infection in African Americans: its natural history and histological progression. Am. J. Gastroenterol., 2002, 9, 700-706.
Nguyen G.C., Thuluvath P.J. Racial disparity in liver disease: biological, cultural, or socioeconomic factors. Hepatology, 2008, 47: 1058-1066.
Ribeiro R.M., Layden-Almer J., Powers K.A., Layden T.J., Perelson A.S. Dynamics of alanine aminotransferase during hepatitis C virus treatment. Hepatology, 2003, 38: 509-517.
Sterling R.K., Stravitz R.T., Luketic V.A., Sanyal A.J., Contos M.J., Mills A.S. et al. A comparison of the spectrum of chronic hepatitis C virus between Caucasians and African Americans. Clin. Gastroenterol. Hepatol., 2004, 2: 469-473.
Sherman K.E. Alanine aminotransferase in clinical practice. A review. Arch. Intern. Med., 1991, 151: 260-265.
Siest G., Schiele F., Galteau M.M., Panek E., Steinmetz J., Fagnani F. et al. Aspartate aminotransferase and alanine aminotransferase activities in plasma: statistical distributions, individual variations, and reference values. Clin. Chem., 1975, 21: 1077-1087.
Sherman K.E., Dodd R.Y. Alanine aminotranferase levels among volunteer blood donors: geographic variation and risk factors. J. Infect. Dis., 1982, 145: 383-386.
Sugimoto K., Stadanlick J., Ikeda F., Brensinger C., Furth E.E., Alter H.J. et al. Influence of the ethnicity in the outcome of hepatitis C virus infection and cellular immune response. Hepatology, 2003, 37: 590-599.
Michielsen P., Brenard R., Bourgeois N., De Galocsy C.H., Delwaide J., Henrion J. et al. Hepatitis C: screening, treatment and prevention practical guidelines. Acta Gastroenterol. Belg., 2003, 66: 15-19.
Khattab M.A., Ferenci P., Hadziyannis S.J., Colombo M., Manns M.P., Almasio P.L. et al. Management of hepatitis C virus genotype 4: Recommendation of an international expert panel. J. Hepatol., 2011, 54: 1250-1262.
Rousseau C.M., Ioannou G.N., Todd-Stenberg J.A., Sloan K.L., Larson M.F., Forsberg C.W. et al. Racial differences in the evaluation and treatment of hepatitis C among veterans: a retrospective cohort study. Am. J. Public Health, 2008, 98: 846-852.
Ge D., Fellay J., Thompson J., Simon J.S., Shianna K.V., Urban T.J. et al. Genetic variation in IL28B predicts hepatitis C treatmentinduced viral clearance. Nature, 2009, 461: 399-401.
Asselah T., De Muynck., Bröet P., Masliah-Planchon J., Blanluet M., Bièche I. et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 of chronic hepatitis C. J. Hepatol., 2012, 56: 527-532.
Nkuize M., Mulkay J.P., Adler M., Lasser L., Michielsen P., de Galocsy C. et al. Response of Black African patients with hepatitis C virus genotype 4 to treatment with peg-interferon and ribavirin. Acta Gastroenterol. Belg., 2013, 76: 291-299.
